News and press
Collaborations, launches and milestones from Mavatar.
Press release
One in 29: Mavatar Takes On the Scariest Numbers in Drug Development
Mavatar, already working with Sobi and other pharma companies, opens its biological intelligence to more drug developers. Built to show which programs are worth pursuing, and which are not. Only one in 29 cancer drugs that enter human trials is ever approved. Mavatar, the biological intelligence behind better-informed decisions, now puts its proprietary DINA technology to work directly on pharma and biotech drug programs. DINA turns large-scale biomedical data into digital disease models that show the biology behind a program, with every answer traceable to its source. The goal is blunt: find out earlier whether a program deserves the next hundred million.
Mavatar enters research collaboration with Clínica Universidad de Navarra on Acute Myeloid Leukemia
Network-based transcriptomics applied to validate candidate biomarkers and explore biological relationships in AML.
Mavatar Launches Alzheimer's Disease Networks at AD/PD 2026
Mavatar today announced the addition of networks of Alzheimer’s disease, glioma and other neurological disorders to its research platform, Mavatar Discovery, enabling researchers and pharmaceutical scientists to explore neurodegenerative disease biology at a systems level. The new resource will be formally introduced to the scientific at the AD/PD International Conference on Alzheimer's and Parkinson's Diseases taking place in Copenhagen from March 17–21, 2026.
Mavatar delivers new data-driven resources to advance precision medicine for IBD
Mavatar, a global specialist in AI and data-driven precision medicine solutions, announces a key milestone in its contribution to the national project “Precision Medicine in Inflammatory Bowel Disease (IBD)”, funded by Vinnova. The company has developed an integrated transcriptomic resource designed to support a broad range of studies within precision medicine for patients with IBD.
Press release
Mavatar Launches Rare Disease Discovery Award
Awarded quarterly through 2026, the Mavatar Rare Disease Discovery Award gives researchers a one-year, full-access license to Mavatar Discovery to study rare diseases where data is scarce.
Press release
Mavatar enters research collaboration with Sobi
Mavatar, a global specialist in AI- and data-driven precision medicine solutions, today announces the start of a non-clinical research collaboration with Sobi, a global biopharmaceutical company focused on rare diseases.
Press release
From Sweden to the world: Mavatar launches a platform that drastically shortens the time to biological insights
Mavatar, the Swedish biotech company pioneering AI- and data-driven precision medicine, today announced the full global commercial launch of Mavatar Discovery, its next-generation platform that enables researchers to analyze complex biological data and uncover disease insights in hours instead of months.
Press release
Mavatar recruits Nordic Life Science profile Ulrika Nyberg
Mavatar, a pioneer in AI- and data-driven precision medicine, is accelerating its momentum following last week’s early commercial launch of the research platform Mavatar Discovery. The company has appointed Ulrika Nyberg as Head of Strategic Partnerships, with a mandate to drive strategic collaborations as Mavatar enters its next growth phase. This recruitment marks the beginning of a broader expansion in the Nordics and a strengthened international presence.
Mavatar announces early commercial release of Discovery
Following extensive development and collaboration with early users, Mavatar Discovery is now being made commercially available to partners, research institutions, and pharmaceutical companies. By combining advanced AI with more than 20 years of scientific innovation, the platform makes it dramatically faster, simpler, and more reproducible to interpret transcriptomic data - a process that has traditionally taken months of manual analysis.
Mavatar establishes U.S. presence and prepares launch of Mavatar Discovery
Swedish healthtech company Mavatar, a pioneer in AI- and data-driven solutions for precision medicine, today announced the opening of its first U.S. office and the upcoming commercial launch of its platform Mavatar Discovery. These developments mark a key step in the company’s international expansion and its mission to revolutionize global healthcare.
· Linda Wakeham
Mavatar lanserar stängd BETA av Mavatar Discovery
Ny plattform för data-driven precisionsmedicin
· Linda Wakeham
Mavatar Recognized as one of Sweden's most Exciting AI Health Companies
In Breakit’s latest overview of Swedish AI companies, Mavatar has been recognized as one of the most exciting players in the healthtech space. Read the full article here (in Swedish)
Press
Press contact
Journalists and media are welcome to get in touch for interviews, images and comments.
